Unknown

Dataset Information

0

Patient subgroup analyses of the treatment effect of subcutaneous interferon ?-1a on development of multiple sclerosis in the randomized controlled REFLEX study.


ABSTRACT: The REFLEX study (NCT00404352) established that subcutaneous (sc) interferon (IFN) ?-1a reduced the risks of McDonald MS (2005 criteria) and clinically definite multiple sclerosis (CDMS) in patients with a first clinical demyelinating event suggestive of MS. The aim of this subgroup analysis was to assess the treatment effect of sc IFN ?-1a in patient subgroups defined by baseline disease and demographic characteristics (age, sex, use of steroids at the first event, classification of first event as mono- or multifocal, presence/absence of gadolinium-enhancing lesions, count of <9 or ?9 T2 lesions), and by diagnosis of MS using the revised McDonald 2010 MS criteria. Patients were randomized to the serum-free formulation of IFN ?-1a, 44 ?g sc three times weekly or once weekly, or placebo, for 24 months or until diagnosis of CDMS. Treatment effects of sc IFN ?-1a on McDonald 2005 MS and CDMS in the predefined subgroups were similar to effects found in the intent-to-treat population. McDonald 2010 MS was retrospectively diagnosed in 37.7 % of patients at baseline. Both regimens of sc IFN ?-1a significantly reduced the risk versus placebo of McDonald 2005 MS and CDMS, irrespective of McDonald 2010 status at baseline (risk reductions between 29 and 51 %). The effect of sc IFN ?-1a was not substantially influenced by baseline patient demographic and disease characteristics, or baseline presence/absence of McDonald 2010 MS.

SUBMITTER: Freedman MS 

PROVIDER: S-EPMC3948518 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6382362 | BioStudies
2018-01-01 | S-EPMC6224000 | BioStudies
2016-01-01 | S-EPMC5075976 | BioStudies
1000-01-01 | S-EPMC5027802 | BioStudies
2020-01-01 | S-EPMC6954891 | BioStudies
2016-01-01 | S-EPMC4999167 | BioStudies
2015-01-01 | S-EPMC4616383 | BioStudies
2016-01-01 | S-EPMC5109953 | BioStudies
2018-01-01 | S-EPMC6248116 | BioStudies
2012-01-01 | S-EPMC3251902 | BioStudies